Skip to Navigation
Skip to Main Content
Skip to Related Content
to view your mail
Yahoo Finance Plus
U.S. markets close in 4 hours 58 minutes
Hepion Pharmaceuticals, Inc. (HEPA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
As of 11:00AM EDT. Market open.
2,754 reactions on $HEPA conversation
Sign in to post a message.
Make sure you have some cash available. There is a big selling pressure in many small cap Bio/Pharma stocks right now.
When will it stop? I don´t know.
What I do know is that it will stop. And when it does, many small cap Bio/Pharma stocks will be oversold, at cash or below cash value, with big value adding catalysts ahead and the trend will reverse, and the uptrend will happen and will be big, where opportunities for a 100 to 500% gain in a short period will present again.
Be patient, learn to sit with cash on hand. Then when the time comes, buy if you need to average down, or buy in, for the uptrend that will come.
Be patient, use this painful season to build a list of stocks that will look good.
HEPA is one to have in that list. If you are able to enter at the right time of the uptrend, all your paper loss or actual losses you may have now you will recover them and much more.
Sometimes the hardest thing to do is do nothing, just sit, watch and wait, save cash, be patient. For those who like fishing this is easier to do. Prepare the bait, prepare the fishing gear, for a great fishing season is coming!!!
Medicines for NASH are almost non existent. I have not seen one set back in any of the HEPA clinical data releases for the last few years. I believe this technology and the drug they have developed will be hugely successful. It is a really tough field with few successes and the street is very skeptical. But based upon the data I believe HEPA will be the diamond in the rough that the NASH community has waited for a long time. This could be a 100 bagger within 3 years - but will be bought out before then if the success continues into early phase 3 trials.
I think is a waste of time to over think what happen here.
For me it is very simple.
We had a great value adding catalyst which we were waiting, I expected on good news for this to pop between 50 to 100% giving around 300 million market cap, and 200 EV which for a positive NASH news and continuation of the program was not crazy to expect.
News came, it was great news. What we got? I took a bath for we got no pop up but a sell off.
Why it happen?
Who cares, I have seen it happen lately with other Bio stocks on good news, instead of pop, it sells off
Now I think what it truly matters is what each one will do with their investment. And that is a personal decision for each one of us. For we are all different and have a different tolerance for risk/reward loss and gain.
This company will have many more opportunities for gains, it has plenty of cash and a good drug to move to the next phase.
Whatever you do, I wish you the best.
hopefully some bad news will come out and the stock will go up?
How can you not have a shareholders annual meeting. Directors can be held liable for the corporate actions. Something smells! Illegal, no quorum, lol.
Shorts/hedge funds took this down today, look at the volume, takes a lot of short shares to keep downward pressure all day, I've seen it 100 times on good news. It will bounce.
No quorum, really, lmao, this is too bad to be true, something is horribly wrong. Stuck in the gutter, gutter ball home gamers.
Good news came, ok go down. No news game, Ok go down. :( I bought heoa with my all of money
Too late to get out...put the seat belt on, and wait for remaining data.
The study update today confirmed the safety of CRV-431 and its effectiveness in reducing an important surrogate marker of NAFLD. I guess, the main reason for the negative market reaction was the non-inclusion of liver biopsy in the study. The biopsy is only applicable for monitoring long-term treatment outcome. The short duration design of this phase IIa study precludes the biopsy inclusion.
The safety is a major plus of CRV-431. Many drugs left the NAFLD/NASH treatment race not because of failing to demonstrate benefit in preventing/reducing liver fibrosis but rather the lack of sufficient safety evidence.
As a side point. The principal investigator of this study (Stephen Harrison) is one of the authors of the American association of the Study of Liver Diseases (AASLD)’s NAFLD treatment guidelines.
If anyone hasn't warned about warrants yet...I talked to Stephen Kilmer, Hepion's IR guy and he told me that the exercise price for the warrants are $108 because they were issued pre-split. That info comes straight from Hepion's CFO. So these are not something you want to buy and hold. The info on the internet that they exercise at $6 is incorrect.
Don't t be scared. Hold and keep buying. I bought 8000 at
Voluuume! Almost 4M🔥 ladies and gentlemen, please take your seat and fasten your seat belt🚀
Buy the dip and you'll be rewarded in the future!
Do your own DD, but the P2 data that rolls in the next 2-3 weeks may send this 25-50% quickly. Be ready. GLTA.
Hepion better bring us some more good news or else they can just completely forget about getting more authorized shares in the shareholder meeting. They failed completely when they thought yesterdays news would be good enough for a big pump up and secured the votes.
The clock is ticking Hepion....
just added another 3k shares....question is, how much lower before 2b results.
Anybody else buying, or are you in wait in see mode?
There are so many catalysts coming for this company. They are sitting on a goldmine. AI-POWR in itself is probably a very valuable asset that a lot of the big pharma want to have. Wouldnt surprise me to see a buyout coming soon. In the billions
Sitting here waiting for that PR
McCormick recalls 3 seasonings for possible salmonella; Walmart, Target, Kroger among stores that sold spices
Starbucks CEO on pricing, mask mandates and China
Yahoo Finance Video
McDonald's Q2 earnings, sales jump on chicken sandwiches, promotions
Advertise with us
© 2021 Verizon Media. All rights reserved.
About Our Ads
Discover new investment ideas by accessing unbiased, in-depth investment research